InvestWiser
Isofol Medical AB
ISOFOL · Nasdaq Stockholm · Healthcare
0.75SEK
−0.5%last day
Price as of 2 October 2026
Performance
1 month
−0.9%
1 year
−6.8%
3 years, per year
−3.3%
5 years, per year
−39.7%
Largest fall, 3 years
−97.9%
Below the peak now
−97.1%
Volatility, 1 year
59.6%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
2.4
Dividend yield
0.0%
Return on equity
−59.6%
Net margin
–
Market value
23 m USD
Quality, value and trend
Where Isofol Medical stands against every Nordic stock today. 100 is best.
67
Profitability and a sound balance sheet over time. Better than 67% of Nordic stocks.
7
The price measured against earnings, assets and cash flow. Better than 7% of Nordic stocks.
45
The price development over the past year. Better than 45% of Nordic stocks.
28
Quality, value and trend together. Better than 28% of Nordic stocks.
About Isofol Medical
Isofol Medical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis